Global New Drug Development Company
Enzychem Lifesciences Corporation is a global pharmaceutical company focused on the development of new and innovative therapies for patients with unmet medical need. With a leading R&D center in Seoul and two GMP manufacturing facilities in Seoul Korea, the company has been developing and producing APIs, contrast imaging agents and innovative new drugs. Based on Enzychem Lifesciences’ EC-18 technology platform, the company is currently developing potential therapies to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, sepsis, acute radiation syndrome and other autoimmune disorders. EC-18, or PLAG, is a naturally synthesized substance, derived from an active ingredient in Sika deer antlers.
At Enzychem Lifesciences, we hold the overarching mission of contributing as much health and happiness to humanity, but with prudence. As our motto states, “We save human lives one at a time.
With the vision of incorporating innovative ideas in the global biopharmaceutical realm, Enzychem strives to drive our continual efforts and sustain strong company spirits with three core values:
- A Venturesome Mindset
At Enzychem, a cardinal value is always carrying the venturesomely bold attitude in search for innovative methods of prevention, treatment, and longevity. Self-doubt and overvaluation of others’ judgement can hinder one’s performance in any context. Conflicting opinions in a world of billions of people is inevitable, and should never lead to second-guessing on nascent ideas before they are shared to others. Embracing a daring mindset is what propels visionary ideas and innovation, all of which Enzychem unwaveringly stands for.
- Trust and Credibility in our Words and Actions
Trust is invaluable, and can be difficult to give and equally challenging to earn. Words carry little to no meaning if they do not align with one’s actions, and thus it is one of Enzychem’s core values that we remain completely honest and credible with the work we conduct. It is only with trust that two individuals, two parties, or two nations can work in joint forces. In an era of world collaboration, Enzychem is always a proponent for honest words and action, as well as the wise exercise of trust.
- The Drive in Going the Extra Mile
Standards are set, but progress can only be achieved when they are exceeded. Momentary success, especially, can breed complacency to the status-quo, implying a sense of ego when stagnation occurs. However, humility is a key virtue that Enzychem holds, as we believe there is always something else to be proved, a greater goal that has yet to be accomplished. In pursuing anything, a principal value we follow is that there is always an opportunity for going the extra mile. Excellence is the key to advancement, especially within the biopharmaceutical industry.
Our team is comprised of not only members from internal operations, but also outside networks, which include a board of directors as well as our scientific advisors. With the collaborative team efforts made between physicians, business leaders, and strategy consultants from both South Korea and the U.S., much of Enzychem’s success thus-far is owed to these individuals, who bring expertise and knowledge in all aspects involved in APIs and global new drug development.
Enzychem’s partnerships involve the joint work with various institutions around the world, namely in South Korea and the United States. Organizations our company has partnered with include the Asan Medical Center and KRIBB.
ASAN Medical Center
Since its establishment in June, 1989, the ASAN Medical Center has grown to become the largest medical institution in Korea, and has achieved a world-class medical reputation, notably for their investment in R&D and clinical treatments.
With the mission of pursuing optimal human health with unwavering passion, and delivering high quality care to all patients, the South Korean medical institute returns its profits back to society and fulfills its founding spirit through free medical services for the less privileged neighbors.
Furthermore, the ASAN Medical Center does not only lend its mission to patients in South Korea, but to those from all over the world. Its numerous partnerships with hospitals and research institutes include those from the U.S., the U.K., and nations all across East and Southeast Asia.
Dr. Myung Hwan Kim of Asan Medical Center is a member of Enzychem Lifesciences’ Board of Directors, and currently leads the clinical development of EC-18.
What was originally established as a Genetic Engineering Research Center in 1985, KRIBB (Korea Research Institute of Bioscience and Biotechnology) now stands as the only government research institute in South Korea dedicated to biotechnology research across a broad span of expertise, including new drug discovery.
KRIBB’s mission extends beyond the national scheme, and strives to carry out R&D and other relevant projects within the field of bioscience and biotechnology in joint effort with other research institutes, academia, and businesses at home and abroad.
The research institute’s project with Enzychem in debuting EC-18 to the U.S. market is only partially exemplary of its global network that spans all over Europe, the Americas, and all of Asia.
Dr. Jae Wha Kim of KRIBB leads Enzychem Lifesciences’ non-clinical studies and is responsible for conducting EC-18’s MoA (Mechanism of Action) study.
Enzychem Lifesciences’ business domain encompasses three sectors, which include global new drug development, APIs (active pharmaceutical ingredients), and health functional foods. The latest project involves the global drug development of EC-18, an immunomodulating drug that presents high potential in treating chemotherapy-induced neutropenia, oral mucositis, psoriasis, and other conditions that result from low immune defenses.
The inception of our company dates back to nearly two decades ago in July of 1999, starting off as a manufacturer for pharmaceutical drugs within South Korea. In passing years, our services and facilities expanded, producing an extensive array of APIs (active pharmaceutical ingredients). By 2011, our company would transform its vision with the endeavor of developing a global new drug we’ve founded ourselves. It was in February of that year when our company was renamed, and Enzychem Lifesciences Corporation was born. Enzychem Lifesciences Corporation is now on the active path to the global new drug development of EC-18, soon to make its debut in the U.S.
Enzychem Lifesciences Corporation
is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal chemistry in July 1999. With its Global New Drug R&D center located in KAIST in Daejeon and its two GMP manufacturing plants in Seoul, it has since been developing and producing APIs and functional health foods, and developing global new drugs as the leader of the field.Read More